-+ 0.00%
-+ 0.00%
-+ 0.00%

LLY.US (LLY.US) “ceptinib tablets” approved for marketing in China

Zhitongcaijing·09/18/2026 13:25:04
Listen to the news

The Zhitong Finance App learned that on September 18, the NMPA official website showed that Lilly Pharmaceuticals (LLY.US)'s new Class 5.1 drug “ceptinib tablets” was approved for marketing in China. According to public information, this is the first time that a ceptinib tablet dosage form has been approved in China. Selpercatinib (Selpercatinib) is a first-of-its-kind small molecule RET inhibitor with high selectivity and inhibitory activity. It has central nervous system (CNS) activity and can inhibit various RET variants. This drug is the world's first approved highly selective RET inhibitor, which works by inhibiting the activity of abnormal RET kinase.

pictures
pictures

Screenshot source: NMPA official website